Document Detail


Use of high-dose cisplatin with aprepitant in an outpatient setting.
MedLine Citation:
PMID:  21883567     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
FURUKAWA N., KAWAGUCHI R. & KOBAYASHI H. (2011) European Journal of Cancer Care Use of high-dose cisplatin with aprepitant in an outpatient setting Chemotherapy-induced nausea and vomiting (CINV) and nephrotoxicity are adverse events induced by cisplatin administration. These effects can be reduced by treatment regimens with low-dose cisplatin, but high-dose cisplatin is still used. In Japan, high-dose cisplatin is usually administered in an inpatient setting to permit management of CINV. However, with use of new-generation antiemetic agents such as aprepitant, CINV and nephrotoxicity are controllable in an outpatient setting. Here, we discuss issues related to the management of high-dose cisplatin administration in outpatients. Grade 2 or worse CINV induced by high-dose cisplatin occurs in more than 40% of patients without treatment with aprepitant, but is controllable by administration of a 5-HT3 receptor antagonist, steroids and aprepitant. Moreover, prevention of CINV using these drugs is cost-effective, since outpatient settings have advantages with regard to health economics and patient quality of life. These findings suggest that shifting high-dose cisplatin administration to the outpatient setting may be achieved with co-administration of aprepitant. Available facilities and the status of the patient should be considered when selecting whether an outpatient setting is suitable for administration of cisplatin, but the use of aprepitant and adequate oral hydration should allow use of cisplatin in this setting.
Authors:
N Furukawa; R Kawaguchi; H Kobayashi
Related Documents :
23351487 - Effects of imod™ and angipars™ on mouse d-galactose-induced model of aging.
22260297 - Intravenous lidocaine has no impact on rocuronium-induced neuromuscular block. randomis...
24476477 - Effects of curcumin on brain-derived neurotrophic factor levels and oxidative damage in...
21735117 - A phase i trial of the farnesyl transferase inhibitor, sch 66336, with temozolomide for...
2553217 - Mk-801 protects against seizures induced by the cholinesterase inhibitor soman.
24392807 - Considerations for new dual-acting bronchodilator treatments for chronic obstructive pu...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-8-25
Journal Detail:
Title:  European journal of cancer care     Volume:  -     ISSN:  1365-2354     ISO Abbreviation:  -     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-9-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9301979     Medline TA:  Eur J Cancer Care (Engl)     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2011 Blackwell Publishing Ltd.
Affiliation:
Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Nara, and Oncology Center, Nara Medical University Hospital, Kashihara, Nara Oncology Center, Nara Medical University Hospital, Kashihara, Nara Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Nara, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High risk of urinary tract infections in post-operative gynaecology patients: a retrospective case a...
Next Document:  Controlling the cost of breast cancer.